| Literature DB >> 34102878 |
Michael Meno1, Justin Abe2, Jami Fukui3, Christa Braun-Inglis3, Ian Pagano3, Jared Acoba1,3,4.
Abstract
Aim: To assess the perception of telehealth visits among a multiracial cancer population during the coronavirus disease 2019 pandemic.Entities:
Keywords: COVID-19; health disparity; pandemic; patient satisfaction; race; telehealth; telemedicine; teleoncology
Mesh:
Year: 2021 PMID: 34102878 PMCID: PMC8202507 DOI: 10.2217/fon-2021-0136
Source DB: PubMed Journal: Future Oncol ISSN: 1479-6694 Impact factor: 3.404
Patient characteristics.
| Characteristic | All patients | Audio only | Audio and video | p-value | |||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| 212 | 100 | 73 | 34.4 | 139 | 65.6 | ||
| 0.09 | |||||||
| Female | 138 | 65.1 | 42 | 57.5 | 96 | 69.1 | |
| Male | 74 | 34.9 | 31 | 42.5 | 43 | 30.9 | |
| 0.23 | |||||||
| <60 | 62 | 29.2 | 16 | 21.9 | 46 | 33.1 | |
| 60–79 | 128 | 60.4 | 49 | 67.1 | 79 | 56.8 | |
| ≥80 | 22 | 10.4 | 8 | 11.0 | 14 | 10.1 | |
| 0.95 | |||||||
| Less than associate | 76 | 35.8 | 27 | 37.0 | 49 | 35.3 | |
| Associate or bachelor's | 105 | 49.5 | 36 | 49.3 | 69 | 49.6 | |
| Master's or doctorate | 31 | 14.6 | 10 | 13.7 | 21 | 15.1 | |
| Prefer not to say | 40 | 18.9 | 12 | 16.4 | 28 | 20.1 | |
| <$30,000 | 35 | 16.5 | 18 | 24.7 | 17 | 12.2 | |
| $30,000–89,999 | 70 | 33.0 | 27 | 37.0 | 43 | 30.9 | |
| ≥$90,000 | 67 | 31.6 | 16 | 21.9 | 51 | 36.7 | |
| 0.91 | |||||||
| Medicare without a supplement, Medicaid, other | 38 | 17.9 | 12 | 16.4 | 26 | 18.7 | |
| Medicare with a supplement | 73 | 34.4 | 26 | 35.6 | 47 | 33.8 | |
| Private | 101 | 47.6 | 35 | 47.9 | 66 | 47.5 | |
| 0.14 | |||||||
| Asian | 130 | 61.3 | 51 | 69.9 | 79 | 56.8 | |
| Native Hawaiian or Pacific Islander | 32 | 15.1 | 7 | 9.6 | 25 | 18.0 | |
| White | 50 | 23.6 | 15 | 20.5 | 35 | 25.2 | |
| 0.06 | |||||||
| 15-min drive or less | 63 | 29.7 | 26 | 35.6 | 37 | 26.6 | |
| 16–30-min drive | 80 | 37.7 | 32 | 43.8 | 48 | 34.5 | |
| More than 30-min drive | 39 | 18.4 | 8 | 11.0 | 31 | 22.3 | |
| Flight | 30 | 14.2 | 7 | 9.6 | 23 | 16.5 | |
| Gastrointestinal | 49 | 23.1 | 23 | 31.5 | 26 | 18.7 | |
| Hematopoietic | 28 | 13.2 | 5 | 6.8 | 23 | 16.5 | |
| Genitourinary | 20 | 9.4 | 10 | 13.7 | 10 | 7.2 | |
| Lung and other | 23 | 10.8 | 7 | 9.6 | 16 | 11.5 | |
| Breast | 92 | 43.4 | 28 | 38.4 | 64 | 46.0 | |
| 0.54 | |||||||
| I do not remember | 45 | 21.2 | 18 | 24.7 | 27 | 19.4 | |
| Stage 0–2 | 97 | 45.8 | 34 | 46.6 | 63 | 45.3 | |
| Stage 3–4 | 70 | 33.0 | 21 | 28.8 | 49 | 35.3 | |
| Telehealth is better or no difference | 139 | 65.6 | 39 | 53.4 | 100 | 71.9 | |
| Office visit is better | 73 | 34.4 | 34 | 46.6 | 39 | 28.1 | |
| 0.28 | |||||||
| Agree | 121 | 57.1 | 38 | 52.1 | 83 | 59.7 | |
| Neutral or disagree | 91 | 42.9 | 35 | 47.9 | 56 | 40.3 | |
Bold values denote statistical significance at the p < 0.05 level.
Figure 1.Patient experiences of the telehealth visit.
Figure 2.Patient-reported preferences for telehealth visits compared with office visits.
Univariate and multivariate linear regression for variables predicting preference for future telehealth visits.
| Factor | Univariate | Multivariate | ||
|---|---|---|---|---|
| Adjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value | |
| 0.73 (0.41–1.29) | 0.27 | 0.69 (0.24–1.92) | 0.47 | |
| 60–79 | 0.90 (0.48–1.66) | 0.73 | 0.38 (0.09–1.61) | 0.19 |
| ≥80 | 0.68 (0.25–1.80) | 0.43 | 0.78 (0.33–1.85) | 0.57 |
| Less than associate | 0.76 (0.32–1.80) | 0.53 | 0.52 (0.15–1.83) | 0.31 |
| Associate or bachelor's | 0.65 (0.29–1.50) | 0.31 | 0.63 (0.18–2.16) | 0.46 |
| Prefer not to say | 0.78 (0.36–1.71) | 0.53 | 0.81 (0.29–2.28) | 0.68 |
| <$30,000 | 1.29 (0.56–2.96) | 0.55 | 2.63 (0.79–8.72) | 0.12 |
| $30,000–89,999 | 1.55 (0.78–3.08) | 0.21 | ||
| Medicare without a supplement, Medicaid, other | 1.03 (0.49–2.19) | 0.93 | 0.77 (0.26–2.31) | 0.65 |
| Medicare with a supplement | 1.34 (0.73–2.48) | 0.34 | 1.16 (0.49–2.71) | 0.74 |
| Asian | ||||
| Native Hawaiian or Pacific Islander | ||||
| 16–30-min drive | 0.87 (0.45–1.70) | 0.69 | 0.69 (0.29–1.67) | 0.42 |
| >30-min drive | 1.08 (0.48–2.42) | 0.86 | 0.63 (0.20–2.03) | 0.44 |
| Flight | 1.30 (0.53–3.17) | 0.57 | 0.39 (0.11–1.38) | 0.15 |
| Gastrointestinal | 0.92 (0.46–1.84) | 0.81 | 0.90 (0.27–3.05) | 0.87 |
| Hematopoietic | ||||
| Genitourinary | 1.78 (0.65–4.86) | 0.26 | 1.38 (0.24–7.83) | 0.72 |
| Lung and other | 2.19 (0.82–5.82) | 0.12 | 2.61 (0.65–10.54) | 0.18 |
| Stage 3–4 | 1.25 (0.67–2.32) | 0.49 | 1.14 (0.45–2.91) | 0.78 |
| I do not remember | 1.14 (0.56–2.32) | 0.73 | 0.74 (0.23–2.33) | 0.61 |
| 1.37 (0.77–2.42) | 0.29 | 2.09 (0.48–2.46) | 0.84 | |
Bold values denote statistical significance at the p < 0.05 level.
OR: Odds ratio.